Last reviewed · How we verify
NCT05700227: ARTIA-Bladder
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
NA trial testing Daily Adaptive External Beam Radiation Therapy in Muscle Invasive Bladder Urothelial Carcinoma in 2 participants. Terminated before completion.
9 May 2024
Quick facts
| Lead sponsor | Varian, a Siemens Healthineers Company |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 2 February 2023 |
| Primary completion | 9 May 2024 |
| Estimated completion | 9 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Daily Adaptive External Beam Radiation Therapy
Conditions studied
- Muscle Invasive Bladder Urothelial Carcinoma — all drugs for Muscle Invasive Bladder Urothelial Carcinoma →
Sponsor
Varian, a Siemens Healthineers Company — full company profile →
Who can join
18 and older, any sex, with Muscle Invasive Bladder Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxicity compared with the historically reported rate for non-adaptive radiation therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 assessment tool will be utilized.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction.
Liu H, Schaal D, Curry H, Clark R, et al · · 2023 · cited 76× · PMID 37660057 · DOI 10.1186/s13014-023-02340-2
Verify or expand the search:
- PubMed search for NCT05700227
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Invasive Bladder Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07061964 — Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva · Phase 2 · recruiting
- NCT07097142 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemothera · Phase 3 · recruiting
- NCT06396533 — Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) · recruiting
- NCT05987241 — Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo · Phase 2, PHASE3 · recruiting
- NCT06257017 — Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma · Phase 2 · recruiting
Other Varian, a Siemens Healthineers Company trials
Trials by the same sponsor.
- NCT06347731 — Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) · NA · completed
- NCT05666193 — On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software · NA · completed
- NCT05524454 — Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy · NA · completed
- NCT05524064 — FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax · NA · active not recruiting
- NCT06338436 — Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05700227 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Varian, a Siemens Healthineers Company
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05700227.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing